Horizon Pharma announced multiple presentations showing that people who have undergone a kidney transplant experience higher rates of uncontrolled gout compared to other renal disease patients, and mortality rates were higher in kidney transplant recipients diagnosed with gout. In addition, a retrospective analysis indicates that gout prevalence remains high among solid organ transplant patients, independent of the use of cyclosporine as an immunosuppressant. These data will be presented at the American Society of Nephrology Kidney Week, Oct. 23-28, in San Diego, Calif. “The remarkable increase of gout in renal transplant patients is concerning,” said Richard J. Johnson, M.D., one of the authors on four ASN analyses discussing solid organ transplant and gout, and professor, Division of Renal Diseases and Hypertension, University of Colorado Denver – Anschutz Medical Campus. “The potential for gout to stimulate inflammatory processes, as well as concern that elevated serum uric acid may have additional effects on blood pressure and kidney function, suggest that this is an important area for further study in the transplant recipient. Treatment of gout in the transplant patient needs more attention.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.